Member Info for EmeraldCarrots

Going forward. Loads in the pipeline.

You only have to look back at the RNS's in the last 6 months.

All IMHO.

Completing Next Generation Sequencing of DNA in cancer patients.

The next step IMHO is to add the ADDITIONAL information analysing LIVE circulating cancer cells (CCT's) caught using Angle's parsortix machine (see Angle's RNS's dated 2nd and 22nd Jan 2024). This would be for patients who have cancer that has spread which happens when CCT's get into the blood stream. This would give the "full picture" of how a cancer is or is not progressing and enable monitoring the effect of any treatment. Thus this could give information to say the treatment is working OR to indicate it is NOT working anabling a different treatment to be tried sooner.

Just waiting for the takeover bid........

Come on Illumina........... or Roche......... or etc..........................

https://www.youtube.com/watch?v=nO-HsxY1afo

All IMHO.

Completing Next Generation Sequencing of DNA in cancer patients.

The next step IMHO is to add the ADDITIONAL information analysing LIVE circulating cancer cells (CCT's) caught using Angle's parsortix machine (see Angle's RNS's dated 2nd and 22nd Jan 2024). This would be for patients who have cancer that has spread which happens when CCT's get into the blood stream. This would give the "full picture" of how a cancer is or is not progressing and enable monitoring the effect of any treatment. Thus this could give information to say the treatment is working OR to indicate it is NOT working anabling a different treatment to be tried sooner.

Just waiting for the takeover bid........

Come on Illumina........... or Roche......... or etc..........................

All IMHO.

Https://www.youtube.com/watch?v=rVZB62WrFHc

LOL!

Up 4.82% now.

Now Angle and others have proved CtDNA simply does not contain all the information a circulating cancer cell (cct) can provide using Angle's Parsortix to obtain the cell FROM A standard BLOOD TEST I don't see how big pharma can ignore Angle any longer. The proof is in the RNS of 4th and 22nd Jan THIS YEAR. So we are just several weeks on and I suspect various Co's will be considersing making an offer for Angle Plc. The currect market cap is only 260,580.000 shares x 16p = £41,692,800. £41m is some sort of bad joke if you ask me.

I suspect we will get an offer more like 50p a share (260,580,000 x 50p = £130,290,000), for starters.

Angle simply do not have the financial muscle to realise the full potential of what they have which is quote incredible.

A large pharma Co. will do the math, buy them, invest and then make a killing as the saying goes.

All IMHO.

In and you will hear why Angle Plc are at the forefront.............................

Just waiting for the buyout. Could it end up being Roche??

https://www.youtube.com/watch?v=OKQGSuOuPkY

All IMHO.

Up 4.02%

Up 1.26%.

Forgot the link:-

More and more negative news about Boeing. I truly am shocked.

https://www.bbc.co.uk/news/business-68409029

Summit in San Diago, California by Brett Swansiger, Chief Commercial Officer, ANGLE Plc.

Our market was closed when the presentation was done as they are 8Hrs behind us.

Hopefully we will see some upward movement in the sp later when the usa market opens about 2:30 Pm.

Lots of extremely interesting other participants too!

See here:-

https://lbx-summit.com/about/agenda/day-one/

The cancer trial involves.

https://www.eisai.com/news/2023/news202330.html

Https://www.bbc.co.uk/articles/c51wyey7v6jo

Great!

California. He is on at 3Pm their time.

https://lbx-summit.com/partners/

https://lbx-summit.com/about/agenda/day-one/

Leisure industry has strong demand then!!!

Should benefit JET2 and WIZZ sp's IMHO.

Synopsis

• Review of epitope-independent harvesting of CTCs from blood for subsequent analysis

• Discuss CTC-DNA and ctDNA combinations as potential predictors of cancer progression, treatment resistance, and relapse

• New Data on the complementary nature of next-generation sequencing of CTC-DNA and ctDNA from a single blood tube

• Potentially enabling longitudinal disease monitoring in real-time to identify mechanisms of resistance in living cancer cells

https://lbx-summit.com/about/agenda/day-one/

Summit in San Diago, California by Brett Swansiger, Chief Commercial Officer, ANGLE Plc.

Lots of extremely interesting other participants too!

See here:-

https://lbx-summit.com/about/agenda/day-one/

Should bode well for WIZZ..........